« Back
Home /
Alectinib

Alectinib

Item no.	HY-13011-50mg
Manufacturer	MedChem Express
CASRN	1256580-46-7
Amount	50 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 200 mg 50 mg 5 mg
Category	Oncology Neuroscience Neural Lineage Markers Neural Transcription Factors Molecular Targets for Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer
Type	Inhibitors
Specific against	other
Purity	99.94
Formula	C30H34N4O2
Citations	Aging Cell. 2020 May;19(5):e13137. Biomed Chromatogr. 2024 Oct;38(10):e5986. bioRxiv. 2020 Dec 16:2020.08.14.251207. bioRxiv. November 12, 2021. Cancer Discov. 2016 Oct;6(10):1118-1133. Cancer Discov. 2018 Jun;8(6):714-729. Cancer Discov. 2024 Sep 13:OF1-OF20. Cancer Lett. 2017 Aug 1;400:61-68. Cell Death Discov. 2018 May 10;4:56. Cell Discov. 2021 May 11;7(1):33. Cell Physiol Biochem. 2018;51(5):1996-2009. Cell Rep Med. 2023 Jan 10;100911. Cell Rep Med. 2024 Mar 19;5(3):101472. Cell. 2025 Mar 6;188(5):1248-1264.e23. Eur J Drug Metab Pharmacokinet. 2021 Jul 18;1-11. Exp Cell Res. 2020 Aug 1;393(1):112054. Fundam Clin Pharmacol. 2021 Feb 1. Harvard Medical School LINCS LIBRARY Heliyon. 2024 Sep 28;10(19):e38637. Mol Syst Biol. 2023 Dec 18. Nat Cancer. 2022 Jun 20. Nat Commun. 2022 Oct 3;13(1):5745. Neoplasia. 2023 May 14;42:100908. Oncogene. 2022 Sep 5. Oncogene. 2022 Sep;41(40):4547-4559. Patent. US20250003968A1. Pharmaceutics. 2023 Oct 11, 15(10), 2449. PLoS One. 2025 Jan 21;20(1):e0308747. Research Square Preprint. 2024 Nov 26. Sci Signal. 2022 Oct 25;15(757):eabm0808. Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. Science. 2014 Oct 3;346(6205):1255784. Science. 2017 Dec 1;358(6367):eaan4368. Transl Oncol. 2021 Jan;14(1):100887. University of California. 2024. Biomolecules. 2024 May 28. Cancer Res. 2022 Feb 1;82(3):484-496. [1]Sakamoto H, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011, 19(5), 679-690. [2]Gadgeel S, et al. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol. 2018 Nov 1;29(11):2214-2222.
Smiles	N#CC1=CC2=C(C3=C(N2)C(C)(C4=CC(N5CCC(CC5)N6CCOCC6)=C(C=C4C3=O)CC)C)C=C1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	CH5424802; RO5424802; RG7853
Shipping condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Anaplastic lymphoma kinase (ALK)
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	482.62
Product Description	Alectinib (CH5424802) is a potent, selective, and orally available ALK inhibitor with an IC50 of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively[1]. Alectinib demonstrates effective central nervous system (CNS) penetration[2].
Manufacturer - Research Area	Cancer
Solubility	DMSO : 4.33 mg/mL (ultrasonic)
Manufacturer - Pathway	Protein Tyrosine Kinase/RTK
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-13011-50mg-safety-datasheet.pdf